Ozempic and Gastroparesis: Examining the Medical Literature on Causation and Risk

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Exposure Concern

For decades, the Immunodeficiency Foundation has served as a trusted editorial archive, preserving the scientific and historical records that illuminate the complexities of human health. Its mission has always been to bridge foundational knowledge with emerging concerns, ensuring that the public and professionals alike can navigate the evolving landscape of medical science. This legacy of translating broad health information into actionable understanding now finds a new and pressing application. As the volume of general health discourse expands, so too does the need to examine specific intersections between widely used therapeutics and unexpected clinical outcomes. One such intersection involves the growing use of glucagon-like peptide-1 receptor agonists, originally developed for metabolic regulation, and reports of delayed gastric emptying severe enough to be classified as gastroparesis. This concern moves beyond the typical scope of general health education into a focused inquiry: what is the relationship between exposure to these agents and the development of this gastrointestinal condition? This transition from a broad health information context to a targeted exposure concern requires careful attention. The shift is not merely about identifying a new risk factor, but about applying the same rigorous, evidence-respecting approach that has always defined the Foundation’s work. The following analysis will therefore examine the documented association between Ozempic exposure and gastroparesis risk, drawing on the Foundation’s commitment to preserving clear, neutral, and historically informed scientific discourse.

Pharmacological Mechanism and Clinical Presentation

Ozempic (semaglutide) is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Its pharmacological action involves slowing gastric emptying, which is a known effect of GLP-1 receptor agonists. This mechanism, while beneficial for glycemic control, raises concerns about the potential for gastroparesis—a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical presentation of gastroparesis overlaps significantly with the gastrointestinal adverse reactions reported in Ozempic clinical trials. In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal symptoms, which are hallmark features of gastroparesis.

Evidence of Gastrointestinal Dysfunction and Mechanistic Pathways

Additional gastrointestinal adverse reactions with a frequency of less than 5% associated with Ozempic include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (placebo 0%, 0.5 mg 2.7%, 1 mg 1.1%), flatulence (placebo 0.8%, 0.5 mg 0.4%, 1 mg 1.5%), gastroesophageal reflux disease (placebo 0%, 0.5 mg 1.9%, 1 mg 1.5%), and gastritis (placebo 0.8%, 0.5 mg 0.8%, 1 mg 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these are not diagnostic of gastroparesis, they are consistent with the spectrum of upper gastrointestinal dysfunction that can accompany delayed gastric emptying. Mechanistically, Ozempic's action as a GLP-1 receptor agonist slows gastric motility via vagal and enteric nervous system pathways. This pharmacodynamic effect is intended to reduce postprandial glucose excursions but can become pathological in susceptible individuals, leading to clinically significant gastroparesis. The timeline between exposure and documented harm is suggested by the pattern of adverse reactions: the majority of nausea, vomiting, and diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), implying that symptoms can emerge early in treatment. However, chronic use may also contribute to persistent or worsening gastroparesis, as the drug's effect on gastric emptying is sustained with continued dosing.

Adequacy of Warnings and Causation Considerations

Regarding adequacy of warnings, the prescribing information for Ozempic does not explicitly list gastroparesis as a contraindication or warning. The label notes that Ozempic has not been studied in patients with a history of pancreatitis and recommends considering other antidiabetic therapies in such patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, there is no specific warning about gastroparesis or delayed gastric emptying as a potential adverse effect. This omission may leave patients and prescribers unaware of the risk, particularly in those with pre-existing gastroparesis or conditions that predispose to it, such as diabetes itself, which is a common cause of gastroparesis. Causation-related considerations for affected patients require careful evaluation. The temporal relationship between Ozempic initiation and onset of gastroparesis symptoms is critical. Patients who develop nausea, vomiting, or early satiety shortly after starting Ozempic or after dose escalation may have drug-induced gastroparesis. Diagnostic confirmation via gastric emptying scintigraphy or breath testing is recommended. Dechallenge (discontinuation of Ozempic) and rechallenge (if clinically appropriate) can help establish causality, though rechallenge is often avoided due to symptom severity. The dose-dependent nature of gastrointestinal adverse reactions supports a causal link, as higher doses (2 mg) were associated with a higher frequency of gastrointestinal adverse reactions (34.0%) compared to 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In summary, the medical literature indicates that Ozempic is associated with gastrointestinal adverse reactions that overlap with gastroparesis symptoms, and the drug's mechanism of action—slowing gastric emptying—provides a plausible pathway for causing or exacerbating gastroparesis. The current labeling does not include a specific warning about gastroparesis, which may represent an adequacy gap in risk communication. Patients who experience persistent gastrointestinal symptoms while on Ozempic should be evaluated for gastroparesis, and discontinuation of the drug should be considered if symptoms are severe or confirmed by diagnostic testing.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the association between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. Clinical trials show a dose-dependent increase in gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea, which overlap with symptoms of gastroparesis. The prescribing information does not include a specific warning for gastroparesis, but the drug's pharmacological effect and reported adverse events suggest a potential risk for causing or exacerbating the condition.

How can patients determine if their gastrointestinal symptoms are due to Ozempic?

Patients who develop symptoms like nausea, vomiting, early satiety, or bloating after starting Ozempic or after a dose increase should consult their healthcare provider. Diagnostic tests such as gastric emptying scintigraphy can confirm gastroparesis. A temporal relationship between drug initiation and symptom onset, along with improvement after discontinuation (dechallenge), supports a causal link. Rechallenge is generally avoided due to symptom severity.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.